ALGS Q4 2023 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-24.2% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$26M-969.7% margin

Net Income

-$28M-1040.4% margin

EPS (Diluted)

$-1.12

QoQ Revenue Growth

-17.2%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$152M

Total Liabilities

$59M

Stockholders' Equity

$92M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-24.2%
Gross Profit	$3M	$4M	-24.2%
Operating Income	-$26M	-$23M	-14.6%
Net Income	-$28M	-$22M	-27.4%